Abstract

The Program in Hematologic Diseases is structured around the Utah Blood and Marrow Transplant Program. The Program is supported by several state-of-the-art clinical laboratories and extensive clinical programs at the University Hospital, the Salt Lake Veterans Affairs Medical Center, the Primary Children's Medical Center, and the LDS Hospital. The Utah BMT Program in Hematologic Diseases has three specific aims. First, to improve the stem cell product used in reconstituting hematopoiesis following myeoablative procedures. Second, to expand the stem cell-marrow donor pool by optimizing recruitment strategies. Third, to define the role of stem cell-marrow transplantation in the treatment of relapsed acute lymphoblastic leukemia neuroblastoma, breast cancer, and acute myeloblastic leukemia relapsing after first allogeneic transplants. The laboratory research component of the program is focused on the biology of the hematopoietic stem cells and the molecular mechanisms regulating hematopoietic stem cell differentiation. The clinical research programs exploit the institution's experience in population genetics, the use of biologic response-modifying agents, molecular diagnostics, and the treatment of hematologic malignancies in children and adults.

  Funding Agency

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
3P30CA042014-14S1
Application #
6503934
Study Section
Project Start
2001-09-27
Project End
2002-04-30
Budget Start
Budget End
Support Year
14
Fiscal Year
2001
Total Cost
Indirect Cost

  Institution

Name
University of Utah
Department
Type
DUNS #
City
Salt Lake City
State
UT
Country
United States
Zip Code
84112

  Publications

Sorenson, Reed S; Deshotel, Malia J; Johnson, Katrina et al. (2018) Arabidopsis mRNA decay landscape arises from specialized RNA decay substrates, decapping-mediated feedback, and redundancy. Proc Natl Acad Sci U S A 115:E1485-E1494
Polanco, Edward R; Western, Nicholas; Zangle, Thomas A (2018) Fabrication of Refractive-index-matched Devices for Biomedical Microfluidics. J Vis Exp :
Camolotto, Soledad A; Pattabiraman, Shrivatsav; Mosbruger, Timothy L et al. (2018) FoxA1 and FoxA2 drive gastric differentiation and suppress squamous identity in NKX2-1-negative lung cancer. Elife 7:
Nevala-Plagemann, Christopher; Francis, Samual; Cavalieri, Courtney et al. (2018) Benefit of adjuvant chemotherapy based on lymph node involvement for oesophageal cancer following trimodality therapy. ESMO Open 3:e000386
Li, Lian; Yang, Jiyuan; Wang, Jiawei et al. (2018) Amplification of CD20 Cross-Linking in Rituximab-Resistant B-Lymphoma Cells Enhances Apoptosis Induction by Drug-Free Macromolecular Therapeutics. ACS Nano 12:3658-3670
Wu, Yelena P; Nagelhout, Elizabeth; Aspinwall, Lisa G et al. (2018) A novel educational intervention targeting melanoma risk and prevention knowledge among children with a familial risk for melanoma. Patient Educ Couns 101:452-459
Tiburcio, Patricia D B; Xiao, Bing; Chai, Yi et al. (2018) IDH1R132H is intrinsically tumor-suppressive but functionally attenuated by the glutamate-rich cerebral environment. Oncotarget 9:35100-35113
Ferris, Elliott; Abegglen, Lisa M; Schiffman, Joshua D et al. (2018) Accelerated Evolution in Distinctive Species Reveals Candidate Elements for Clinically Relevant Traits, Including Mutation and Cancer Resistance. Cell Rep 22:2742-2755
Liang, Wenjie; Yang, Pengfei; Huang, Rui et al. (2018) A Combined Nomogram Model to Preoperatively Predict Histologic Grade in Pancreatic Neuroendocrine Tumors. Clin Cancer Res :
Ou, Judy Y; Fowler, Brynn; Ding, Qian et al. (2018) A statewide investigation of geographic lung cancer incidence patterns and radon exposure in a low-smoking population. BMC Cancer 18:115

Showing the most recent 10 out of 1193 publications